Physician profile
Andrew D Rogove
NPI 1295783132
$2,138.13
in general payments reported to CMS, 2019-2025
10 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $150 · 2023: $311 · 2024: $588 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363 · Consulting Fee: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.13 |
| Consulting Fee | $475.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $600.00 | 2019-2025 | Tysabri |
| Abbvie INC. | $456.45 | 2023-2025 | Qulipta |
| Medtronic, INC. | $213.17 | 2023-2024 | Linq II, Solitaire X |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Argenx US, INC. | $155.94 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Stryker Corporation | $137.68 | 2025 | Surpass Evolve |
| Silk Road Medical, INC. | $125.17 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Penumbra, INC. | $105.30 | 2024 | Red 72 |
| Cardiva Medical, INC. | $89.49 | 2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Ceribell, INC. | $79.93 | 2025 | Pocket Eeg Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rogove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.